Skip to main content
MPLT
NASDAQ Life Sciences

MapLight Posts $51.6M Q3 Loss, $463.4M Cash Through 2028

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$7.37
Mkt Cap
$402.924M
52W Low
$6.06
52W High
$40.43
52W Position info
22% above low
Off High info
82% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

MPLT sits 22% above its 52-week low of $6.06.

Summary

MapLight reported a $51.6 million Q3 loss and $463.4 million in cash, enough to fund operations through 2028. It also disclosed a timeline discrepancy on ZEPHYR-2 topline (2H 2027 in the headline vs 2028 in the body) and is pausing preclinical spending.


Key Events · Earnings and Guidance · MPLT

  • Q3 Loss Widens to $51.6M

    Net loss was $51.6 million ($0.97 per share) vs $29.4 million ($37.18 per share) in Q3 2025; R&D rose to $44.2 million and G&A to $11.1 million.

  • Cash Runway Through 2028

    Cash, cash equivalents and investments totaled $463.4 million as of September 30, 2026, expected to fund operations through 2028.

  • ZEPHYR-2 Timeline Conflict

    The release headline says ZEPHYR-2 topline in 2H 2027, but the body says 2028; start-up activities have begun ahead of an FDA End-of-Phase 2 meeting.

  • Preclinical Spending Paused

    MapLight is pausing significant further investment in preclinical and discovery-stage programs to focus resources on ML-007C-MA.


Analysis · MPLT · Life Sciences

The balance sheet is the story here: $463.4 million in cash funds operations through 2028, past the ZEPHYR-2 and VISTA readouts, even as the Q3 loss of $51.6 million ($0.97/share) widened from a year ago. The filing also flags a timeline inconsistency — the headline says ZEPHYR-2 topline in 2H 2027 while the body says 2028 — and confirms the company is pulling back from preclinical/discovery spending to concentrate on ML-007C-MA. For a clinical-stage biotech, cash runway and trial timing are what move the stock.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MPLT was trading at $7.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $402.9M. The 52-week trading range was $6.06 to $40.43. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MPLT - Latest Insights

MPLT
Nov 16, 2026, 7:15 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $7.25
Real-time Price: $7.37 info
Change: +$0.120 (+2%) info
Market Cap: $402.924M info
MPLT
Aug 18, 2026, 6:55 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $11.59
Real-time Price: $7.37 info
Change: -$4.22 (-36%) info
Market Cap: $402.924M info
MPLT
Aug 18, 2026, 6:51 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $11.59
Real-time Price: $7.37 info
Change: -$4.22 (-36%) info
Market Cap: $402.924M info
MPLT
Aug 13, 2026, 5:01 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $11.70
Real-time Price: $7.37 info
Change: -$4.33 (-37%) info
Market Cap: $402.924M info
MPLT
Aug 13, 2026, 4:51 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.70
Real-time Price: $7.37 info
Change: -$4.33 (-37%) info
Market Cap: $402.924M info